Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
40 hedge funds and large institutions have $9.58M invested in Viracta Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
71% more capital invested
Capital invested by funds: $5.61M → $9.58M (+$3.97M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 42 → 40 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.4K |
| 2 |
Renaissance Technologies
New York
|
+$17.2K |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$12.8K |
| 4 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$8.32K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$6.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$123K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$104K |
| 3 |
Morgan Stanley
New York
|
-$41.4K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$39.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.6K |
VIRX Hedge Fund Activity: Q1 2024 in Review
40 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2024, worth a combined $9.58M — up 71% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VIRX and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, adding an estimated $26.4K. The largest seller was UBS Group, cutting an estimated $123K.
- 40 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2024, down from 42 in Q4 2023.
- Funds reported $9.58M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2024, up 71% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2024 and 6 closed out, a net change of -2 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2024 was Citadel Advisors, an estimated $26.4K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2024 was UBS Group, an estimated $123K sold.
Based on aggregated 13F filings for Q1 2024.